Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease
- PMID: 17089032
Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease
Abstract
Certain chemokines have been proposed to distinctly contribute to tumor growth, dissemination and local immune escape. Expression of the chemokine receptor CXCR4 has been linked to tumor progression in diverse tumor entities. The aim of this study was to evaluate if the expression of CXCR4 influences progression of human pancreatic cancer. CXCR4 expression of pancreatic cancer was retrospectively assessed by immunohistochemistry in 103 patients with pancreatic cancer. Intensity of CXCR4 expression was correlated with both tumor and patient characteristics. Human pancreatic cancer revealed variable intensities of CXCR4 expression. Strong CXCR4 expression was significantly associated with advanced UICC stages (P=0.03) and revealed a trend for hematogenous metastasis (P=0.09) and progressed local tumor stages (P=0.15). In summary, strong expression of CXCR4 was significantly associated with advanced pancreatic cancer.
Similar articles
-
Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma.BMC Cancer. 2006 Dec 18;6:290. doi: 10.1186/1471-2407-6-290. BMC Cancer. 2006. PMID: 17176471 Free PMC article.
-
Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer.Int J Oncol. 2009 Feb;34(2):473-80. Int J Oncol. 2009. PMID: 19148483
-
Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer.Clin Cancer Res. 2005 Mar 1;11(5):1743-50. doi: 10.1158/1078-0432.CCR-04-1195. Clin Cancer Res. 2005. PMID: 15755995
-
Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis.Anticancer Res. 2009 Nov;29(11):4751-8. Anticancer Res. 2009. PMID: 20032431
-
Mass spectrometry based proteomic profiling for pancreatic cancer.JOP. 2010 Sep 6;11(5):423-6. JOP. 2010. PMID: 20818108 Review. No abstract available.
Cited by
-
Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.Cancer Gene Ther. 2014 Jul;21(7):264-74. doi: 10.1038/cgt.2014.26. Epub 2014 Jun 6. Cancer Gene Ther. 2014. PMID: 24903014 Free PMC article.
-
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets.Clin Cancer Res. 2022 Nov 14;28(22):4957-4967. doi: 10.1158/1078-0432.CCR-22-0275. Clin Cancer Res. 2022. PMID: 36112544 Free PMC article.
-
SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway.Cancer Lett. 2012 Sep 28;322(2):169-76. doi: 10.1016/j.canlet.2012.02.035. Epub 2012 Mar 23. Cancer Lett. 2012. PMID: 22450749 Free PMC article.
-
Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.Gut. 2008 Oct;57(10):1456-68. doi: 10.1136/gut.2008.150052. Gut. 2008. PMID: 18791122 Free PMC article. Review.
-
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).BMC Cancer. 2014 Jul 1;14:476. doi: 10.1186/1471-2407-14-476. BMC Cancer. 2014. PMID: 24981311 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
